GET THE MOST ON DRUG SUPPLY CHAIN & PRICES

Dr Gamal Khalafalla Mohamed Ali

Dr Gamal Khalafalla Mohamed Ali is qualified as a pharmacist from Khartoum University, where he also did his PG diploma in health economics. He has an MSc in pharmaceutical services and medicines control from University of Bradford, UK. Gamal has finished his PhD in 2006, in the Nottingham Trent University-UK. He has over 25 years working as a pharmacist in medicines supply management and regulatory authority in Sudan. It was within this period (1992 to 2017) that he worked as a manager for RDF in Khartoum state, Ministry of Health. Then he shifted to the Federal Directorate of Pharmacy as a manager for Pharmaceutical services and planning department. In November 2007, he has been appointed to be the secretary general of the National Medicines and Poisons Board, the Medicine Regulatory Authority of Sudan. Dr. Gamal has developed measures for efficient supply chain and stock level control at all levels across Khartoum State, as well as proactively advocating establishment of the Revolving Drug Fund in different states of Sudan.

Contact me!

BOOKS

SUPPLY CHAIN

3,121 Days in the Driving Seat of the National Medical Supplies Fund: Lessons to be Shared for Future Application

PUBLISHED: 7 OCTOBER 2020

Written by the former Director General of the National Medical Supplies Fund (NMSF) of Sudan, 3,121 Days in the Driving Seat of the National Medical Supplies Fund explores the lessons Dr Gamal Khalafalla Mohamed Ali learned while leading Supply Chain Transformation across the NMSF.

This book provides a roadmap for Supply Chain leaders aiming to make their Medical Supply Agencies financially self-sustaining, and it is particularly useful for those working in lower-income contexts. The text covers essential topics for Supply Chain Transformation, including the role of leadership, human resources and automation in Supply Chain Transformation, as well as particular initiatives Dr Mohamed Ali undertook to encourage the NMSF’s growth. This book is a necessary text for leaders across Public Health Supply Chains in lower-income countries, and it provides a transparent view of the lessons Dr Mohamed Ali learned as a key architect in the NMSF’s transformation.

SHORTAGE OF MEDICINES

The Impact of the RDF on Accessibility of Medicines: Experience of Khartoum State – Sudan

PUBLISHED: 29 JUNE 2010

The frequent shortages of medicines in public health care facilities obliged those who could afford it to go to the private sector. This situation was disadvantageous to the poor, because they did not have protected access to free services at public health facilities. The situation also led to the overburdening of service provision at the referral hospitals thus increasing their cost. In addition, poor health services could increase morbidity and mortality from preventable diseases, especially among the vulnerable members of the community (for example, women, children and the elderly) in both urban and rural communities. Moreover, the shift from low level primary facilities to referral hospitals increased the cost of health service provision.

This book demonstrates how security for the endangered structure of RDF can be established and presents reasons for its success, and its achievements and pitfalls. The medicines’ quality measures applied by the largest Revolving Drug Fund of its kind in the world will also add to the existent Cost-Sharing literature.

MEDICINES PRICES

Value for Money: Improving Health Outcomes from Expenditure on Drugs

PUBLISHED: 14 DECEMBER 2016

While advances in health technology over the last several decades have greatly improved life span and welfare in society, it is often perceived that the cost of these innovations has not been adequately offset by their benefit. Increased health care budgets in most countries have emphasized the need to demonstrate value for money from expenditure on health technologies.

This book aims to establish measures that secure the provision of safe and effective quality medicines to Sudanese patients at reasonable prices.The strategies that are advocated throughout the book are based on the premise that the best value for money does not necessarily mean the lowest initial price option, but rather the best return on the money spent to meet the population’s need for medicines and other medical technologies.

Website Design & Development DESIGNPLEX.PK | Powered by © 2020 DESIGNPLEX.CA